Development of Highly Potent Noncovalent Inhibitors of SARS- CoV-2 3CLpro

文献类型： 外文期刊

第一作者： Hou, Ningke

作者： Hou, Ningke;Hou, Ningke;Hou, Ningke;Shuai, Lei;Zhong, Gongxun;Wang, Chong;He, Xijun;Huo, Hong;Bu, Zhigao;Shuai, Lei;Zhong, Gongxun;Wang, Chong;He, Xijun;Bu, Zhigao;Zhang, Lijing;Zhang, Wenyi;Tan, Qiaozhu;Gao, Haishan;Xu, You;Xue, Jing;Peng, Chen;Yu, Hongtao;Huang, Jing;Hu, Qi;Zhang, Lijing;Xie, Xuping;Zou, Jing;Shi, Pei-Yong;Tang, Kaiming;Yuan, Shuofeng;Zhu, Yunkai;Yu, Yin;Zhang, Rong;Menachery, Vineet;Su, Wenji;Yuan, Youlang;Shen, Zuyuan

作者机构：

期刊名称：ACS CENTRAL SCIENCE （ 影响因子：18.2； 五年影响因子：17.1 ）

ISSN： 2374-7943

年卷期： 2023 年

页码：

收录情况： SCI

摘要： The 3C-like protease (3CLpro) is an essential enzyme for the replication of SARS-CoV-2 and other coronaviruses and thus is a target for coronavirus drug discovery. Nearly all inhibitors of coronavirus 3CLpro reported so far are covalent inhibitors. Here, we report the development of specific, noncovalent inhibitors of 3CLpro. The most potent one, WU-04, effectively blocks SARS-CoV-2 replications in human cells with EC50 values in the 10-nM range. WU-04 also inhibits the 3CLpro of SARS-CoV and MERS-CoV with high potency, indicating that it is a pan-inhibitor of coronavirus 3CLpro. WU-04 showed anti-SARS-CoV-2 activity similar to that of PF-07321332 (Nirmatrelvir) in K18-hACE2 mice when the same dose was administered orally. Thus, WU-04 is a promising drug candidate for coronavirus treatment.

分类号：

  • 相关文献
作者其他论文 更多>>

微信小程序